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study was to evaluate structured chiropodist care (CC) with
regard to healing rates and costs provided by intensively
instructed professionals. METHODS: One year follow-up-data
of a randomized and controlled trial (RCT) performed in the
province of Styria, Austria showed signiﬁcantly reduced reulcer-
ation rates under chiropodist care. Patients in the intervention
group received chiropodist care in average 11 times per year and
were reimbursed for the costs (€29 per visit). Based on a pub-
lished paper Austrian speciﬁc cost data of 2001 were used to
build a Markov Model to evaluate 10 years outcome. A Monte-
Carlo-Simulation (n = 10.000) was performed for patients with
chiropodist care (intervention) and no chiropodist care (control).
RESULTS: Mean follow-up-duration for 91 patients of the RCT
was 386 days with a reulceration rate of 36% in the interven-
tion group (n = 47) and 55% in the control group (p = 0.05).
The model calculation over 10 years showed treatment costs per
patient of €12,094 (SD 13,379) in the intervention and €18,538
(SD 16,120) in the control group. Costs for the general treat-
ment of diabetes were not taken into account. The amputation
rate under intervention declined to 40% versus 67% in the
control group. Taking the mean life expectancy into account (6.1
vs. 5.1ys.) average costs per patient-year were 1.985 € in the
intervention group versus €3.654 in the control group. CON-
CLUSION: The model based analysis demonstrated the beneﬁt
of CC over a 10 year period in terms of reduced amputation rates
and lower costs per patient and year.
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OBJECTIVES: Hyperglycemia in the critically ill, non-diabetic
patient has been shown to negatively affect clinical outcomes.
Administration of continuous insulin infusion (CII) to maintain
blood glucose (BG) between 80–110mg/dL has thus become
standard of care. The objective of this study was to compare the
costs and BG levels associated with glucose control among
patients pre- and post-CII protocol implementation in an inten-
sive care unit (ICU). METHODS: Combination of time-in-
motion (TIM) observations and retrospective random chart
review to compare glucose control and costs in 2001 and 2004,
prior to and after CII implementation respectively. TIM data
determined time spent on activities related to glucose manage-
ment and chart data determined frequency of respective activi-
ties per year. Study population included ICU patients >16 years
old, mechanically ventilated for >12 hours, with no diagnosis of
diabetes. Costs were determined for glucose monitoring with no
insulin orders (2001), glucose management with sliding scale
subcutaneous insulin (2001), and management with CII proto-
col (2004) using 2005 US$ from the hospital perspective.
RESULTS: From a total 460 charts in 2001, 49 (11%) were
reviewed. From a total 540 charts in 2004, 83 (15%) were
reviewed. No differences in age, gender, marital status, or race
by year were noted (p > 0.05). Costs (mean +/-SD) associated
with monitoring and no insulin were $0.16 +/-0.56 (median =
$0.00) per patient day, with subcutaneous insulin $10.08 
+/-4.96 (median = $8.42), and with CII protocol $21.87 +/-3.90
(median = $22.49). Mean +/-SD daily blood glucose values 
were 138mg/dL +/-24, 157mg/dL +/-32, and 108mg/dL +/-10,
respectively. Regression analysis demonstrated statistical differ-
ences in BG (p < 0.01) by method. CONCLUSION: Costs asso-
ciated with CII protocol are more than twice the costs of sliding
scale subcutaneous orders per patient day, but result in recom-
mended BG values below 110mg/dL. Impact of costs on hospi-
tal policy will be discussed.
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OBJECTIVES To evaluate the long-term clinical and economic
outcomes of adding Niaspan® to statin treatment in Type-2 dia-
betes patients with persistently low HDL-c. METHODS Two
models were developed to project long-term clinical and eco-
nomic beneﬁts. The ﬁrst simulated the evolution of lipid levels
with treatment utilising second order Monte Carlo methodology,
and the second was designed to calculate the risk of coronary
heart disease (CHD) events each subsequent year using standard
Markov modeling techniques. Transition probabilities for CHD
events were derived from the Framingham risk formulae. Base-
line cohort characteristics and simvastatin treatment effects were
taken from the 4S clinical trial (diabetes sub-group). Patients
with persistently low HDL-c (<1mmol/L) on statin treatment
received either add-on Niaspan® or continued statin monother-
apy. Treatment effects of Niaspan® were taken from several clin-
ical studies summarized in the European SPC. Direct costs (2004
Euros) were accounted from a third party payer perspective.
Annual discount rates of 5% (Germany) and 3% (Sweden) were
applied to clinical outcomes and costs. RESULTS A total of
23.42% of patients were projected to have persistently low
HDL-c levels after statin treatment. In these patients mean undis-
counted life expectancies of 19.72 years and 19.13 years were
projected for the Niaspan® and statin monotherapy arms respec-
tively (undiscounted difference 0.59 years). Improvements in 
discounted life expectancy were 0.26 and 0.35 years respec-
tively for Germany and Sweden. Lifetime direct medical costs
were higher by €6,038 in Germany and €6,170 (SEK 56,308) 
in Sweden with addition of Niaspan®. Incremental cost-
effectiveness ratios based on discounted life expectancies were
€23,404 in Germany and €17,538 (SEK 160,099) per life year
gained in Sweden for statin plus Niaspan® versus statin
monotherapy. CONCLUSIONS In Germany and Sweden, addi-
tion of Niaspan® to statin treatment was highly cost-effective in
Type-2 diabetes patients with persistently low HDL-c compared
to statin monotherapy.
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OBJECTIVES: To compare the long-term cost-effectiveness of
adding Niaspan® to statin treatment in diabetic and non-diabetic
patients with persistently low HDL c. METHODS: Two models
were developed to project long-term clinical and economic out-
comes. The ﬁrst model (Monte Carlo simulation) was used to
evaluate the impact of simvastatin treatment on lipid levels and
identify patients with low HDL-c. Baseline cohort characteristics
were taken from the diabetic sub-population of the 4S study. In
